Modulation of dystrophia myotonica-protein kinase (DMPK) expression
US9765338B2 · kind B2 · utility
57Cited by
45References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2015 |
| Grant date | Sep 19, 2017 |
| Priority date | — |
| Expiry date | Jul 30, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3525
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.